Polycystic liver disease (PCLD) is characterized by a large number of liver cysts scattered throughout the liver parenchyma. We herein intend to present the beneficial effect of palliative fenestration treatment on quality of life in a patient with symptomatic PCLD. A 48-year-old female patient had been followed up for 5 years for both polycystic liver and kidney diseases at another institution. During follow-up for last 1 year, we recognized that she had barely maintained her ability of function in daily activities due to progressive worsening of fatigue and dyspnea on exertion. The patient finally underwent surgical fenestration treatment. Multiple cysts in the enlarged liver were opened and the cyst walls were excised with electrocautery. No surgical complication occurred and the patient was discharged 10 days after the open fenestration surgery. The total liver volume was 3,870 ml before surgery and 3,125 ml at 1 week after surgery, showing a volume reduction of 19.3%. After surgery, her performance status improved significantly. In the present case, significant improvement in quality of life and daily activity performance was achieved after open fenestration treatment over 18 months of follow-up without disease recurrence. 
INTRODUCTION
Polycystic liver disease (PCLD) is characterized by a large number of liver cysts scattered throughout the liver parenchyma. This disease entity is usually associated with autosomal dominant polycystic kidney disease. Patients with autosomal dominant polycystic kidney disease have polycystic kidneys, a feature that is absent in patients with autosomal dominant PCLD. 1 Symptoms are often absent in patients with PCLD until there is a significant increase in cyst size. They mainly include abdominal pain, early satiety, dyspnea, nausea, and vomiting. 2 Treatment is indicated if the symptom becomes severe or intolerable, and the therapeutic intention is to decrease the total liver volume leading to relief of compression-related symptoms. 3, 4 Most of the PCLD patients present with only disturbing symptoms that deteriorate health quality and limit daily activities rather than causing serious liver function-related complications.
There are several therapeutic options, including aspiration-sclerotherapy, cyst fenestration, partial liver resection, and liver transplantation. The choice of treatment usually depends on the number, size, and location of the liver cysts. 5 The technique of fenestration of liver cysts was first described in 1968, 6 which was reported to be a safe and effective treatment for the management of symptomatic non-parasitic cysts of the liver. 7 In this study, we intend to present the beneficial effect of palliative fenestration treatment on quality of life in a patient with symptomatic PCLD.
CASE
A 48-year-old female patient had been followed up for (Table 1) , 10 and type C according to Schnelldorfer's classification (Table 2) .
11
Magnetic resonance imaging study revealed water-filled multiple liver and kidney cysts (Fig. 3) .
After obtaining consent of the patient on the uncertain effect of fenestration treatment as well as high risk of disease recurrence, the patient underwent surgical fenestration treatment. Multiple cysts in the enlarged liver were opened and the cyst walls were excised with electrocautery (Fig. 4) . To avoid bleeding and bile leakage, the thin membranous portions were meticulously fenestrated and none of the viable normal liver parenchyma was resected. The majority of accessible liver cysts were opened. At the end of the fenestration procedure, the liver appeared to be markedly shrunken. Three Jackson-Pratt type drains were inserted to evacuate the ascitic fluid: the abdominal drainage output was about 500 ml/day at post- and laparoscopic fenestration has been summarized in the literature. 16 Immediate symptom relief is achieved in 92% of the patients, whereas up to 25% experience recurrence of the cysts or symptoms. 17 Complication rate after fenestration is in the range of 23% while mortality is about 2%.
Factors that predict failure of fenestration are previous abdominal procedures, deep-seated cysts, incomplete unroofing, cysts in segments VII and VIII, and the presence of diffuse PCLD. 17 Hepatic resection is usually reserved for highly symptomatic patients who are incapacitated by their disease due to the massive expansion of their livers. 9 In such patients, fenestration alone is rarely successful because the liver parenchyma is rigid and it does not collapse. 17 Symptom relief is achieved in 86% of the patients although cyst recurrence is expected in one third of the patients. 18 The morbidity rate associated with this procedure can be up to 50% and includes ascites, pleural effusions, biliary leakage, and hemorrhage. One of the reasons for these complications is the fact that there is a significant distortion of the intra-hepatic vasculature and biliary tree which makes these procedures technically very challenging.
Orthotopic liver transplantation is the only curative Sharing (KONOS) is often unable to assist this group of patients. For these patients, MELD exception criteria seem to be necessary. 20, 21 Because of the shortage of available grafts, the need for life-long immunosuppression, and the perioperative risks, liver transplantation is indicated only in symptomatic patients (Fig. 6 ). In the current Korean setting in which the majority of deceased donor liver grafts are allocated to urgent patients, most patients with PCLD have a very low chance of receiving deceased donor liver grafts; therefore, some of them have undergone living donor liver transplantation. 22, 23 In patients with PCLD, patient selection, timing and choice of treatments can be very challenging. In symptomatic patients, treatment strategies should be based on the degree and progression of symptoms and the severity of other medical conditions. Symptomatic patients with large cysts or limited hepatic involvement might benefit from fenestration or sclerotherapy. Hepatic resection with or without fenestration should be favored in patients with diffuse involvement of the liver but with sufficiently preserved parenchyma. Finally, in the patients with diffuse disease, liver transplantation is a valid option and should be pursued as primary therapy prior to the development of debilitating disease that can significantly increase the risks of perioperative adverse events. 16 In the present case, significant improvement in quality of life and daily activity performance was achieved after open fenestration treatment over 18 months of follow-up without disease recurrence.
